Active Ingredient: Ipilimumab
Ipilimumab in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 1 milligrams ipilimumab per kilogram of body weight, once every 3 weeks, 4 doses in total.
The recommended dose is 1 mg/kg ipilimumab in combination with 3 mg/kg nivolumab administered intravenously every 3 weeks for the first 4 doses. This is then followed by a second phase in which nivolumab monotherapy is administered intravenously at either 240 mg every 2 weeks or at 480 mg every 4 weeks, as presented in the following table. For the monotherapy phase, the first dose of nivolumab should be administered;
Recommended doses and infusion times for intravenous administration of ipilimumab in combination with nivolumab:
| Combination phase, every 3 weeks for 4 dosing cycles | Monotherapy phase | |
|---|---|---|
| Nivolumab | 3 mg/kg over 30 minutes | 240 mg every 2 weeks over 30 minutes or 480 mg every 4 weeks over 60 minutes |
| Ipilimumab | 1 mg/kg over 30 minutes | - |
Treatment with ipilimumab in combination with nivolumab, should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient (and up to maximum duration of therapy if specified for an indication).
Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment with ipilimumab in combination with nivolumab for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.
Liver function tests (LFTs) and thyroid function tests should be evaluated at baseline and before each dose of ipilimumab. In addition, any signs or symptoms of immune-related adverse reactions, including diarrhoea and colitis, must be assessed during treatment with ipilimumab.
The recommended infusion period is 30 minutes.
Ipilimumab must not be administered as an intravenous push or bolus injection.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
